Reuters: Regulatory News: UPDATE 1-U.S. approves GSK, Xenoport drug for new use

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-U.S. approves GSK, Xenoport drug for new use Jun 7th 2012, 11:08 LONDON, June 7 | Thu Jun 7, 2012 7:08am EDT LONDON, June 7 (Reuters) - GlaxoSmithKline and XenoPort have received approval from the U.S. Food and Drug Administration to sell Horizant to treat post-herpetic neuralgia, the companies said on Thursday. The medicine is already approved as a treatment for restless legs syndrome. XenoPort will receive a milestone payment of $10 million from GSK following first sales of the drug in its new use.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions